02.03.26 -- December 2025 — CDMO Opportunities And Threats Report

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

Improving your ADC’s chance of clinical success requires an understanding of what potential obstacles lie ahead and what capabilities and expertise are necessary to overcome them.

Thorough characterization is key to unlocking the potential of antibody-based therapeutics. Leveraging a CDMO's extensive capabilities can allow you to navigate the biopharmaceutical development landscape.

Blending pharmaceuticals and medical devices into a single product offers immense potential for patient care, but manufacturing these combination products presents unique hurdles.

Conducted alongside the Faculty of Medicine at Palacky University and supported by the Technology Agency of the Czech Republic, this project focused on translating research into a viable product.

Uncover how a data-driven approach to small-scale studies not only accelerates development timelines but also enhances decision-making and resolves full-scale manufacturing challenges across modalities.

Examine how a CMO can deliver significant value to drug developers by fostering successful outsourcing relationships, streamlining the path to market, and supporting demands.

Experienced outsourcing partners will have the right facility and technical capabilities, a culture of speed and execution, and shared expectations and commitment to continuous improvement.

Learn about a validated autoinjector design that aligns with a widely used reference standard, offers proven usability, and helps simplify regulatory pathways for tirzepatide delivery programs.